Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 11/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312197 | 0.82 | L3MBTL1 (0.50) | AOC3SIGMAR1RAB9ANPC1MAPT | |
| SCHEMBL1314155 | 0.78 | KDM4C (0.46) | AOC3RAB9ANPC1HRH1MAPT | |
| SCHEMBL21914805 | 0.74 | AOC3 (0.53) | AOC3RAB9ANPC1MAPT | |
| SCHEMBL9822796 | 0.71 | TGFBR1 (0.41) | AOC3 | |
| SCHEMBL1312572 | 0.69 | NPC1 (0.68) | AOC3RAB9ANPC1HPGD | |
| SCHEMBL1312565 | 0.69 | NPC1 (0.68) | AOC3RAB9ANPC1HPGD | |
| SCHEMBL21914583 | 0.69 | AOC3 (0.57) | AOC3RAB9ANPC1MAPTMTOR | |
| SCHEMBL10693416 | 0.68 | KCNH2 (0.38) | AOC3 | |
| SCHEMBL1313667 | 0.68 | NPC1 (0.65) | AOC3RAB9ANPC1 | |
| SCHEMBL21888993 | 0.67 | AOC3 (1.00) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| WO-2010033701-A2 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | SPHK1, SPHK2, S1PR1 | AOC3 1777/4885ADRB2 1940/4885SIGMAR1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.